ALMS Anticipate a positive readout from the Phase 2B LUMUS study in Q3 will support SLE as an additional indication for ALMS' envudeucitinib
ALMS Anticipate a positive readout from the Phase 2B LUMUS study in Q3 will support SLE as an additional indication for ALMS' envudeucitinib @ OPCO
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.